Citations

Clear

203 citation(s) found for "Alberts, Steven".

A retrospective analysis of gemcitabine and nab-paclitaxel for the treatment of metastatic cholangiocarcinoma.
Soyano, Aixa , Kung, Shu Ting, Mody, Kabir , Soyano, Aixa , Mittra, Arjun , Borad, Mitesh J. , Alberts, Steven R.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: e15616-e15616

10.1200/jco.2017.35.15_suppl.e15616 Get It

e15616 Background: Cholangiocarcinoma (CCA) is a progressively fatal disease with an annual incidence of 1-2 cases per 100,000 people in the USA. Complete surgical resection is the only curative option for CCA. However, the majority of patients (pts) have advanced disease at diagnosis, and those undergoing resection often develop local or distant recurrence. Gemcitabine and Cisplatin remains the only standard chemotherapeutic regimen for advanced CCA. Alternative and improved therapies are critically needed. Gemcitabine/nab-Paclitaxel (GA) is a regimen that has become standard therapy in advanced pancreatic cancer (PDAC). Given the morphologic and histologic similarities between PDAC and CCA, this regimen has been used in advanced CCA, but no data exists regarding its efficacy in this disease. The goal of our study is to evaluate the Mayo Clinic experience with GA for the treatment of metastatic CCA. Methods: We retrospectively analyzed records from adult pts at Mayo Clinic with metastatic cholangiocarcinoma who received at least 2 cycles of GA. Our aims were to assess the progression-free survival (PFS), overall survival (OS) and disease response. Results: We analyzed 9 pts, 3 male and 6 female. The median age at diagnosis was 50 years (range 41-64). Six pts had metastatic disease at diagnosis while 3 underwent surgery with subsequent distant disease recurrence. Pts received a median of 2 lines (range 0-5) of systemic therapy prior to receiving GA, and a median of 2 cycles (range 2-15) of GA. At the time of our analysis, 4 of the 9 pts (44%) had died. The median OS from initiation of GA was 7.3 months (95% CI 1.7- 12.9) and median PFS from initiation of GA was 4.7 months (95% CI 0.48-8.9). The best overall responses using RECIST criteria were: partial response in 1 (11%), stable disease in 5 (55%) and disease progression in 3 (33%) pts. One pt remained on therapy 14.9 months after initiating GA. Conclusions: In our study, the combination of gemcitabine and nab-paclitaxel has demonstrated similar OS and PFS as other systemic therapies. To the best of our knowledge, this is the first report of this regimen in CCA. Ongoing, prospective trials are currently evaluating this regimen in advanced CCA.
Genetic correlates of therapeutic toxicities of stage III colon carcinoma patients treated with adjuvant FOLFOX+/-cetuximab (NCCTG N0147, Alliance).
Hua, Xinwei , Banbury, Barbara L. , Phipps, Amanda I. , Kocarnik, Jonathan, Harrison, Tabitha A. , Thibodeau, Stephen N. , Chan, Emily , Goldberg, Richard M. , Kahlenberg, Morton S., Nair, Suresh , Shields, Anthony F. , Jahagirdar, Balkrishna, Peters, Ulrike , Harrison, Tabitha A , Newcomb, Polly A. , Sun, Wei , Shi, Qian , Sinicrope, Frank A. , Gill, Sharlene , Alberts, Steven R. , Chan, Andrew T.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: 3604-3604

10.1200/jco.2017.35.15_suppl.3604 Get It

3604 Background: Limited research has investigated the role of variation in the host genome as a determinant of colon carcinoma (CC) outcomes, including toxicity due to therapeutic agents. We examined the relationship between germline genetic factors and treatment-associated serious adverse events (SAEs) in a population of CC patients in which treatment was standardized and follow-up for outcomes was uniformly conducted. Methods: Using existing biospecimens from CC patients with resected stage III disease in a phase III randomized trial of FOLFOX adjuvant chemotherapy with and without cetuximab (NCCTG N0147), genome-wide genotyping arrays were conducted for 2200 patients for a total of ~20 million single nucleotide polymorphisms (SNPs). Using logistic regression models we assessed SNP-specific associations with SAEs, utilizing a discovery-based approach to search the genome in an unbiased manner. Detailed information on SAEs was collected using the Common Toxicity Criteria for Adverse Events (CTCAE, v3.0). Analyses evaluating associations with specific classes of common grade ≥3 SAEs were performed, including gastrointestinal toxicities, neutropenia, and paresthesias. A threshold of P < 5x10-8was used to denote genome-wide significance. Results: Among patients who received FOLFOX, several SNPs on chr 15 near the ANP32A gene and on chr 2 near the CD207 gene were statistically significantly associated with grade ≥3 neuropathy. The strongest SNP-specific associations in these regions were in the range of odds ratio (OR) = 1.3, P = 2.8×10−10 and OR = 1.5, P = 2.7×10−10, respectively. Conclusions: Findings from this genome-wide analysis demonstrate the potential importance of germline genetic variation in influencing CC patients’ experience of specific toxicities to FOLFOX regimens. These results highlight two genomic regions of potential interest for understanding the biological mechanism for such toxicities, although further evaluation and replication is needed. Support: U10CA180821, U10CA180882, U10CA180820, U10CA180863, U10CA180888, CCSRI 021039, R01CA176272, Eli Lilly & Co, Pfizer, Sanofi. Clinical trial information: NCT00079274 .
Association of immune markers and Immunoscore with survival of stage III colon carcinoma (CC) patients (pts) treated with adjuvant FOLFOX: NCCTG N0147 (Alliance).
Hermitte, Fabienne , Heying, Erica N., Benson, Al B. , Goldberg, Richard M. , Kahlenberg, Morton S., Nair, Suresh , Shields, Anthony F. , Galon, Jerome , Sinicrope, Frank A. , Shi, Qian , Gill, Sharlene , Sargent, Daniel J. , Galon, Jérôme , Alberts, Steven R.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: 3579-3579

10.1200/jco.2017.35.15_suppl.3579 Get It

3579 Background: Tumor infiltrating lymphocytes (TIL) indicate a host immune response that may influence survival. Immunoscore was developed using CD3+ and CD8+density and location in primary CC pts with pooled stages, varying treatment and follow-up. We determined if individual immune markers and/or Immunoscore are prognostic in resected stage III CC pts (N=600). Methods: CD3+ and CD8+ T-cell or CD20+ B lymphocyte density in central tumor (CT) and invasive margin (IM) was evaluated by immunostaining and quantified by image analysis. Immunoscore was calculated on a scale of I0 to I4 with high densities of CD3+ and CD8+in both CT and IM scored as I4; low densities scored as I0. Associations with disease-free survival (DFS) were evaluated by multivariable Cox regression adjusting for covariates. Results: Data for CD3+, CD8+ and CD20+ were generated (N=595). Higher density of CD3+ CT, CD3+ IM and CD8+ IM were associated with longer DFS adjusting for covariates (Table). CD3+ IM had the strongest association with DFS, and was stronger in left-sided (HRadj.=0.81, 95% CI, 0.70-0.94, padj.= 0.0049) vs right-sided (HRadj.=0.93, 95% CI, 0.85-1.0 padj.=0.52) tumors (pinteraction=0.039). Higher density of CD3+ IM was associated with older age (p=0.034), T1/2 (p<.0001), N1 (p=0.017), right-sided (p=0.013), high TILs (p=0.0008), and deficient MMR (p=0.0003). Using a prior Immunoscore risk stratification, higher scores were associated with better DFS (HR.=0.62, CI, 0.44-0.87, p=0.006) (Table). Conclusions: Densities of CD3+ and CD8+, especially at IM, are individually prognostic in FOLFOX-treated pts. Association of CD3+IM with prognosis differed by primary CC site. Immunoscore was strongly prognostic, and this result provides validation in a clinical trial cohort. [Table: see text]
Analysis of serum vitamin D levels and prognosis in stage III colon carcinoma patients treated with adjuvant FOLFOX+/- cetuximab chemotherapy: NCCTG N0147 (Alliance).
Smyrk, Thomas C. , Goldberg, Richard M. , Heying, Erica N., Cohen, Steven J., Kahlenberg, Morton S., Nair, Suresh , Shields, Anthony F. , Jahagirdar, Balkrishna, Sinicrope, Frank A. , Shi, Qian , Gill, Sharlene , Sargent, Daniel J. , Pollak, Michaël , Alberts, Steven R.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: 3516-3516

10.1200/jco.2017.35.15_suppl.3516 Get It

3516 Background: Epidemiological data suggest a protective effect of vitamin D on CC risk. However, association of serum vitamin D level with clinical outcome in pts with surgically resected CC remains unknown. We analyzed total circulating 25-hydroxyvitamin D [25(OH)D)] with clinical outcome in pts with resected stage III CC treated with FOLFOX +/- cetuximab in a phase III trial. Methods: Association of pre-treatment level of plasma 25(OH)D with disease-free survival (DFS) and time-to-recurrence (TTR) was analyzed with 25(OH)D as a continuous variable by a relative risk model with splines and as a binary variable (vitamin D deficient [<30 ng/mL]) using multivariable Cox regression. Results: Overall, 49% (291/600) of pts were vitamin D deficient. Prevalence of vitamin D deficiency was significantly higher in women vs men (52% vs. 48%, p=0.030) and in blacks vs whites (74% vs. 45%, p=0.0003). The continuous 25(OH)D level and pt sex were associated by the interaction test (pinteraction=0.044). There were no statistically significant associations with DFS/TTR for either continuous 25(OH)D level (DFS, p=0.22; TTR, p=0.26) nor for vitamin D deficiency (DFS, adjusted hazard ratio [HRadj]=1.01, 95% CI, 0.74-1.38; padj=0.94; TTR, HRadj=1.00; CI, 0.72-1.38; padj=0.99. A comparison of the highest vs lowest tertile showed a significant association between the highest 25(OH)D level and better outcomes in men (DFS, HRadj.=0.18, CI, 0.04-0.76, padj=0.020; TTR, HRadj.=0.12, CI, 0.02-0.64, padj=0.014), but not in women (DFS, pinteraction=0.039; TTR, pinteraction=0.033). Conclusions: Nearly one-half of pts in the clinical trial cohort were vitamin D deficient with lowest 25(OH)D levels found in women and blacks. While vitamin D deficiency was not associated with adverse outcome, high levels of vitamin D in men, but not women, were associated with longer survival. Support: U10CA180821, U10CA180882, U10CA180820, U10CA180863, U10CA180888, U10CA077202, CCSRI 021039. ClinicalTrials.gov Identifier: NCT00079274.
RUCAPANC: An open-label, phase 2 trial of the PARP inhibitor rucaparib in patients (pts) with pancreatic cancer (PC) and a known deleterious germline or somatic BRCA mutation.
Hendifar, Andrew , Geva, Ravit , Epelbaum, Ron, Vonderheide, Robert H. , Wolff, Robert A. , Giordano, Heidi, Goble, Sandra, Shroff, Rachna T. , Domchek, Susan M. , McWilliams, Robert R. , Biankin, Andrew V. , Alberts, Steven R. , Lin, Kevin

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 4110-4110

10.1200/jco.2016.34.15_suppl.4110 Get It

Association of adverse events (AEs) with outcomes in early stage colon cancer (CC): An analysis of 10,695 CC patients from the ACCENT database.
Grothey, Axel, Haller, Daniel G. , Gramont, Aimery de , Twelves, Christopher , Goldberg, Richard M. , Cheung, Winson Y. , André, Thierry , Kerr, Rachel , Dixon, Jesse G. , Alberts, Steven R. , O’Connell, Michael J. , Saltz, Leonard B. , Lonardi, Sara , Yoshino, Takayuki , Yothers, Greg , Shi, Qian

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 3601-3601

10.1200/jco.2018.36.15_suppl.3601 Get It

Validation of tumor infiltrating lymphocytes (TIL) and tumor budding as predictors of prognosis in patients with stage III colon cancers treated in a FOLFOX-based adjuvant trial: NCCTG N0147 (Alliance).
Lee, Hee Eun , Foster, Nathan R. , Smyrk, Thomas C. , Sinicrope, Frank A. , Shi, Qian , Alberts, Steven R.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 3583-3583

10.1200/jco.2018.36.15_suppl.3583 Get It

Association of sex and adverse events (AEs) of adjuvant chemotherapy (ACT) in early stage colon cancer (CC): A pooled analysis of 28,636 patients (pts) in the ACCENT database.
Haller, Daniel G. , Allegra, Carmen J. , VanCutsem, Eric, Gramont, Aimery de , Twelves, Chris, Blanke, Charles D. , Francini, Guido, Goldberg, Richard M. , Wagner, Dorothea , Grothey, Axel , André, Thierry , Dixon, Jesse G. , Wolmark, Norman , George, Thomas J. , Alberts, Steven R. , O’Connell, Michael J. , Saltz, Leonard B. , Kerr, Rachel , Yothers, Greg , Shi, Qian

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 3603-3603

10.1200/jco.2018.36.15_suppl.3603 Get It

CD3+ and CD8+ tumor-infiltrating lymphocyte (TIL) densities to prognostically stratify DNA mismatch repair-deficient (dMMR) colon cancer patients (pts): NCCTG N0147 (Alliance).
Yoon, Harry H. , Heying, Erica N., Murányi, Andrea , Ough, Faith , Djalilvand, Azita, Clements, June, Bowermaster, Rebecca, Shanmugam, Kandavel , Shi, Qian , Liu, Wenwei , Barnes, Michael, Alberts, Steven R. , Sinicrope, Frank A.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 3598-3598

10.1200/jco.2018.36.15_suppl.3598 Get It

Genome-wide association with survival in stage II-III colon cancer clinical trials (NCCTG N0147, Alliance for Clinical Trials in Oncology; NSABP C-08, NRG Oncology).
Banbury, Barbara L. , Allegra, Carmen J. , Peters, Ulrike , Nair, Suresh , Harrison, Tabitha A. , Goldberg, Richard M. , Lucas, Peter C. , Colangelo, Linda H., Atkins, James N., Harrison, Tabitha A , Lucas, Peter C , Penney, Kathryn , Shi, Qian , Alberts, Steven R. , Yothers, Greg , Sinicrope, Frank A. , Sun, Wei , Newcomb, Polly A. , Chan, Andrew T.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 3582-3582

10.1200/jco.2018.36.15_suppl.3582 Get It